High dose and frequency Extended-release Lansoprazole (Dexlansoprazole) and Amoxicillin dual therapy for Helicobacter pylori infections

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001758

Enrollment

Registered

2016-01-06

Start date

2015-12-03

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : High dose dual therapy consists of 30 mg of dexlansoprazole and 750 mg of amoxicillin q.i.d. for 14 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Either sex in age of 18 to 85 2) Among patients with active/inactive peptic ulcer diagnosed from endoscopy, those who have come up with benign helicobacter after an examination (a rapid urease test) 3) Among patients with no organic disorders from endoscopy but with indigestion, those who have been diagnosed with benign helicobacter after an examination (a rapid urease test) and those who are willing to get a bacteria-removal treatment 4) Among patients who received endoscopic mucosal resection or submucosal dissection to treat gastric adenoma or early gastric cancer, those with benign helicobacter diagnosed from an examination 5) Those who have signed a written subject consent to join the experimentation

Exclusion criteria

Exclusion criteria: 1) Patients who have refused to participate in the experimentation 2) Patients who have been cured by the helicobacter eradication 3) Patients who have taken drugs for the last two weeks which would affect a bacteria examination and treatment (proton pump inhibitor, antibiotics, H2-receptor antagonist and bismuth) 4) Patients who are on steroids, aspirin and antithrombotic 5) Patients who have gone through a gastric operation (a gastric mucosal resection excluded) 6) Patients with severe heart disease, lung disease, hormonal disorder 7) Patients with severe problems in kidney and liver 8) Patients with blood disease 9) Patients with cancer 10) Expecting mother or patients with chances to be pregnant 11) Patients who have allergies to the test drug

Design outcomes

Primary

Measure	Time frame
eradication rate	—

Secondary

Measure	Time frame
safety and tolerability	—

Countries

Korea, Republic of

Contacts

Public ContactSeong Woo Jeon

Kyungpook National University Medical Center

sw-jeon@hanmail.net+82-53-200-2602

Outcome results